PLYMOUTH, Mich.--(BUSINESS WIRE)--
Esperion Therapeutics, Inc. (Nasdaq:ESPR), a clinical-stage
biopharmaceutical company focused on developing and commercializing
first-in-class, oral, low-density lipoprotein cholesterol (LDL-C)
lowering therapies for the treatment of hypercholesterolemia, today
announced that it will host a conference call and webcast on Tuesday,
September 3, 2013 at 8:30 a.m. Eastern Time (ET) to present top-line
results from a Phase 2a clinical study of its lead product candidate,
ETC-1002, as an add-on to statin therapy in patients with
hypercholesterolemia.
The live event will be accessible on the Esperion website beginning at
8:30 a.m. at www.esperion.com,
under the Investors section, or by calling (877) 312-7508 (domestic) or
(253) 237-1184 (international). The access code is 28976349. A replay of
the event will be available beginning at approximately 10:00 a.m. ET on
September 3, 2013 from the Esperion website or by calling (855) 859-2056
(domestic) or (404) 537-3406 (international), using access code
28976349. The replay will be available through September 17, 2013.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a biopharmaceutical company focused on
the research, development and commercialization of therapies for the
treatment of patients with elevated levels of LDL-C and other
cardiometabolic risk factors. ETC-1002, Esperion's lead product
candidate, is a unique, first-in-class, orally available, once-daily
small molecule designed to lower levels of LDL-C and to avoid side
effects associated with existing LDL-C lowering therapies. ETC-1002 is
targeted for statin intolerant patients with elevated levels of LDL-C.
Esperion has completed seven clinical studies to date, including four
Phase 2a studies, and expects to initiate a robust Phase 2b clinical
program in the fourth quarter of 2013. For more information, please
visit www.esperion.com.
Forward Looking Statements
This press release contains forward-looking statements that are made
pursuant to the safe harbor provisions of the federal securities laws,
including statements regarding the anticipated timing of Esperion's
Phase 2b clinical program. Any statements contained in this press
release that are not statements of historical fact may be deemed to be
forward-looking statements. Forward-looking statements involve risks and
uncertainties that could cause Esperion's actual results to differ
significantly from those projected, including, without limitation, the
risk that unanticipated developments could interfere with the
development (and commercialization) of ETC-1002, as well as other risks
detailed in Esperion's filings with the Securities and Exchange
Commission, including our Quarterly Report on Form 10-Q filed with
Securities and Exchange Commission on August 12, 2013. You are cautioned
not to place undue reliance on the forward-looking statements, which
speak only as of the date of this release. Esperion disclaims any
obligation or undertaking to update or revise any forward-looking
statements contained in this press release, other than to the extent
required by law.
BrewLife
Denise Powell
510-703-9491
dpowell@brewlife.com
Source: Esperion Therapeutics, Inc.
News Provided by Acquire Media